Press
Release

Altimmune to Announce Third Quarter 2020 Financial Results on November 10

November 3, 2020 at 8:00 AM EST

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.

Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.

Conference Call Details

Date: Tuesday, November 10th
Time: 8:30 am Eastern Time
Domestic: 877-300-8521
International: 412-317-6026
Conference ID: 10149733
Webcast: http://public.viavid.com/index.php?id=142319

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:    
Will Brown   Ashley R. Robinson
Chief Financial Officer   LifeSci Advisors, LLC
Phone: 240-654-1450   617-430-7577
wbrown@altimmune.com   arr@lifesciadvisors.com
     
Media Contacts:    
Warren Rizzi    
Sard Verbinnen & Co.    
Phone: 212-687-8080    
altimmune-svc@sardverb.com    

Altimmune Logo.png

Source: Altimmune, Inc.

 

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe